Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype Clinical Trials in New York, New York
2 recruitingNew York, New York
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Glioblastoma IDH (Isocitrate Dehydrogenase) WildtypeAstrocytoma, Grade III
Debiopharm International SA116 enrolled17 locationsNCT05765812
Recruiting
Phase 1
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
GlioblastomaGBMGlioblastoma Multiforme+4 more
Orbus Therapeutics, Inc.66 enrolled8 locationsNCT05879367